Nordea Investment Management AB Has $1.19 Million Stock Position in Sarepta Therapeutics, Inc. $SRPT

Nordea Investment Management AB raised its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 1.6% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 69,363 shares of the biotechnology company’s stock after purchasing an additional 1,066 shares during the period. Nordea Investment Management AB owned approximately 0.07% of Sarepta Therapeutics worth $1,185,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Ancora Advisors LLC increased its holdings in shares of Sarepta Therapeutics by 150.0% during the first quarter. Ancora Advisors LLC now owns 500 shares of the biotechnology company’s stock worth $32,000 after buying an additional 300 shares in the last quarter. Pandora Wealth Inc. bought a new stake in Sarepta Therapeutics during the first quarter valued at $45,000. Brooklyn Investment Group boosted its position in Sarepta Therapeutics by 450.4% during the first quarter. Brooklyn Investment Group now owns 721 shares of the biotechnology company’s stock valued at $46,000 after acquiring an additional 590 shares during the last quarter. Banque Transatlantique SA bought a new stake in Sarepta Therapeutics during the first quarter valued at $44,000. Finally, Hurley Capital LLC boosted its position in Sarepta Therapeutics by 139.2% during the first quarter. Hurley Capital LLC now owns 1,435 shares of the biotechnology company’s stock valued at $92,000 after acquiring an additional 835 shares during the last quarter. 86.68% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on SRPT shares. Wells Fargo & Company lifted their price target on Sarepta Therapeutics from $48.00 to $50.00 and gave the company an “overweight” rating in a research note on Thursday, August 7th. Citigroup initiated coverage on shares of Sarepta Therapeutics in a report on Tuesday, July 22nd. They issued a “sell” rating for the company. Sanford C. Bernstein started coverage on shares of Sarepta Therapeutics in a research report on Tuesday, July 29th. They issued a “market perform” rating and a $13.00 target price on the stock. Wall Street Zen upgraded shares of Sarepta Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 9th. Finally, Bank of America increased their price objective on shares of Sarepta Therapeutics from $16.00 to $18.00 and gave the company an “underperform” rating in a research report on Wednesday. Eight equities research analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and seven have given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $34.46.

Sarepta Therapeutics Price Performance

Shares of NASDAQ SRPT opened at $21.89 on Friday. Sarepta Therapeutics, Inc. has a 52 week low of $10.41 and a 52 week high of $138.81. The stock has a market capitalization of $2.14 billion, a price-to-earnings ratio of -25.16 and a beta of 0.51. The firm has a 50-day simple moving average of $19.88 and a 200-day simple moving average of $28.49. The company has a quick ratio of 1.81, a current ratio of 2.89 and a debt-to-equity ratio of 0.84.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings data on Wednesday, August 6th. The biotechnology company reported $2.02 EPS for the quarter, beating the consensus estimate of $0.89 by $1.13. Sarepta Therapeutics had a negative net margin of 2.34% and a negative return on equity of 1.03%. The business had revenue of $611.09 million during the quarter, compared to analyst estimates of $530.66 million. During the same quarter last year, the firm posted $0.07 earnings per share. The business’s revenue for the quarter was up 68.4% compared to the same quarter last year. On average, equities analysts predict that Sarepta Therapeutics, Inc. will post 2.67 earnings per share for the current fiscal year.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.